Ivaylo Gentschev

Dr. Ivaylo Gentschev

Biochemistry, University of Würzburg, Würzburg, Bavaria, Germany
orcid

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 December 2007 in Cancer Gene Therapy
Verified
Journal Article
Closed access
JFJ Fensterle
J Fensterle
BBB Bergmann
B Bergmann
CYC L R P Yone
C L R P Yone
CHC Hotz
C Hotz
SMS R Meyer
S R Meyer
IGIvaylo Gentschev
Ivaylo Gentschev

4 January 2012 in Journal of Translational Medicine
Verified
Journal Article
Open access
PDF file
SPSandeep S Patil
Sandeep S Patil
IGIvaylo Gentschev
Ivaylo Gentschev
INIngo Nolte
Ingo Nolte
GOGregory Ogilvie
Gregory Ogilvie
ASAladar A Szalay
Aladar A Szalay
Oncolytic viruses refer to those that are able to eliminate malignancies by direct targeting and lysis of cancer cells, leaving non-cancerous tissues unharmed. Several oncolytic viruses including adenovirus strains, canine distemper virus and vaccinia virus strains have been used for canine cancer therapy in preclinical studies. However, in contrast to human studies, clinical trials with oncolytic viruses for canine cancer patients have not been reported. An 'ideal' virus has yet to be identified. This review is focused on the prospective use of oncolytic viruses in the treatment of canine tumors - a knowledge that will undoubtedly contribute to the development of oncolytic viral agents for canine cancer therapy in the future.

20 July 2015 in Viruses
Verified
Journal Article
Open access
PDF file
MAMarion Adelfinger
Marion Adelfinger
SBSimon Bessler
Simon Bessler
AFAlexa Frentzen
Alexa Frentzen
ACAlexander Cecil
Alexander Cecil
JLJohanna Langbein-Laugwitz
Johanna Langbein-Laugwitz
ASAladar A. Szalay
Aladar A. Szalay
Virotherapy on the basis of oncolytic vaccinia virus (VACV) strains is a novel approach for canine cancer therapy. Here we describe, for the first time, the characterization and the use of VACV strain GLV-5b451 expressing the anti-vascular endothelial growth factor (VEGF) single-chain antibody (scAb) GLAF-2 as therapeutic agent against different canine cancers. Cell culture data demonstrated that GLV-5b451 efficiently infected and destroyed all four tested canine cancer cell lines including: mammary carcinoma (MTH52c), mammary adenoma (ZMTH3), prostate carcinoma (CT1258), and soft tissue sarcoma (STSA-1). The GLV-5b451 virus-mediated production of GLAF-2 antibody was observed in all four cancer cell lines. In addition, this antibody specifically recognized canine VEGF. Finally, in canine soft tissue sarcoma (CSTS) xenografted mice, a single systemic administration of GLV-5b451 was found to be safe and led to anti-tumor effects resulting in the significant reduction and substantial long-term inhibition of tumor growth. A CD31-based immuno-staining showed significantly decreased neo-angiogenesis in GLV-5b451-treated tumors compared to the controls. In summary, these findings indicate that GLV-5b451 has potential for use as a therapeutic agent in the treatment of CSTS.

9 February 2005 in BMC Cancer
Verified
Journal Article
Open access
PDF file
IGIvaylo Gentschev
Ivaylo Gentschev
JFJoachim Fensterle
Joachim Fensterle
ASAndreas Schmidt
Andreas Schmidt
TPTamara Potapenko
Tamara Potapenko
Jakob TroppmairJakob Troppmair
Jakob Troppmair
URUlf R Rapp
Ulf R Rapp
Background: Serine-threonine kinases of the Raf family (A-Raf, B-Raf, C-Raf) are central players in cellular signal transduction, and thus often causally involved in the development of cancer when mutated or over-expressed. Therefore these proteins are potential targets for immunotherapy and a possible basis for vaccine development against tumors. In this study we analyzed the functionality of a new live C-Raf vaccine based on an attenuated Salmonella enterica serovar Typhimurium aroA strain in two Raf dependent lung tumor mouse models. Methods: The antigen C-Raf has been fused to the C-terminal secretion signal of Escherichia coli α-hemolysin and expressed in secreted form by an attenuated aroA Salmonella enterica serovar Typhimurium strain via the α-hemolysin secretion pathway. The effect of the immunization with this recombinant C-Raf strain on wild-type C57BL/6 or lung tumor bearing transgenic BxB mice was analyzed using western blot and FACS analysis as well as specific tumor growth assays. Results: C-Raf antigen was successfully expressed in secreted form by an attenuated Salmonella enterica serovar Typhimurium aroA strain using the E. coli hemolysin secretion system. Immunization of wild-type C57BL/6 or tumor bearing mice provoked specific C-Raf antibody and T-cell responses. Most importantly, the vaccine strain significantly reduced tumor growth in two transgenic mouse models of Raf oncogene-induced lung adenomas. Conclusions: The combination of the C-Raf antigen, hemolysin secretion system and Salmonella enterica serovar Typhimurium could form the basis for a new generation of live bacterial vaccines for the treatment of Raf dependent human malignancies.

16 May 2014 in Viruses
Verified
Journal Article
Open access
PDF file
IGIvaylo Gentschev
Ivaylo Gentschev
SPSandeep S. Patil
Sandeep S. Patil
IPIvan Petrov
Ivan Petrov
JCJoseph Cappello
Joseph Cappello
MAMarion Adelfinger
Marion Adelfinger
ASAladar A. Szalay
Aladar A. Szalay
Cancer is the leading cause of disease-related death in companion animals such as dogs and cats. Despite recent progress in the diagnosis and treatment of advanced canine and feline cancer, overall patient treatment outcome has not been substantially improved. Virotherapy using oncolytic viruses is one promising new strategy for cancer therapy. Oncolytic viruses (OVs) preferentially infect and lyse cancer cells, without causing excessive damage to surrounding healthy tissue, and initiate tumor-specific immunity. The current review describes the use of different oncolytic viruses for cancer therapy and their application to canine and feline cancer.

20 February 2021 in Methods and Protocols
Verified
Journal Article
Open access
PDF file
Mingyu YeMingyu Ye
Mingyu Ye
MWMartina Wilhelm
Martina Wilhelm
IGIvaylo Gentschev
Ivaylo Gentschev
ASAladar Szalay
Aladar Szalay
Stable cell lines are widely used in laboratory research and pharmaceutical industry. They are mainly applied in recombinant protein and antibody productions, gene function studies, drug screens, toxicity assessments, and for cancer therapy investigation. There are two types of cell lines, polyclonal and monoclonal origin, that differ regarding their homogeneity and heterogeneity. Generating a high-quality stable cell line, which can grow continuously and carry a stable genetic modification without alteration is very important for most studies, because polyclonal cell lines of multicellular origin can be highly variable and unstable and lead to inconclusive experimental results. The most commonly used technologies of single cell originate monoclonal stable cell isolation in laboratory are fluorescence-activated cell sorting (FACS) sorting and limiting dilution cloning. Here, we describe a modified limiting dilution method of monoclonal stable cell line selection using the real-time fluorescence imaging system IncuCyte®S3.